<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23308">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01823913</url>
  </required_header>
  <id_info>
    <org_study_id>G-0081</org_study_id>
    <nct_id>NCT01823913</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetic Comparison of Exforge® and G-0081 in Healthy Male Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Severance Hospital</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates safety and pharmacokinetic comparison of G-0081, a combination
      tablet of amlodipine and valsartan (test formulation), and Exforge®, a combination tablet of
      amlodipine and valsartan (reference formulation) for single dose in healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Profile of Pharmacokinetics</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 144, 192 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax, Area Under Curve(0 to the last sampling time)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 144, 192 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tmax, Area Under Curve(0 to infinity), T_1/2</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Test and reference formulations</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test formulation and reference formulation given orally 14 days apart in a fasted state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test formulation</intervention_name>
    <description>A single oral dose of a combination tablet of amlodipine orotate 10mg and valsartan 160mg</description>
    <arm_group_label>Test and reference formulations</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference formulation</intervention_name>
    <description>A single oral dose of a combination tablet of amlodipine besylate 10mg and valsartan 160mg</description>
    <arm_group_label>Test and reference formulations</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers between the ages of 20 and 50 and within 20% of their ideal
             body weight, without congenital abnormality or chronic disease

        Exclusion Criteria:

          -  History of cardiovascular, pulmonary, renal, endogenous, gastrointestinal,
             hematologic, neurologic or hemorrhagic disease;

          -  Clinically significant findings on routine laboratory (hematology, serum chemistry
             and urinalysis) or ECG tests;

          -  Use of prescription drugs in the 14 days immediately prior to starting the study that
             had the potential to interact with the study medication;

          -  Use of any substance that could induce or inhibit drug metabolism enzymes
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 9, 2013</lastchanged_date>
  <firstreceived_date>March 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Severance Hospital</investigator_affiliation>
    <investigator_full_name>Kyungsoo Park</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
